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The contact system (CS) consists of three proteins (factor XII [FXII], 
prekallikrein [PK], and H‐kininogen [HK, high molecular weight kini‐
nogen]) that comprise the initiators of the so‐called intrinsic blood 
coagulation system. The first protein in the hemostatic pathway of 
intrinsic blood coagulation associated with bleeding is factor XI (FXI), 
a substrate of FXIIa. This report, which is focused on introducing 
a consensus nomenclature for the three CS proteins and FXI, will 
describe each protein. However, this consensus report is not in‐
tended to be a review of the field; hence, the statements are not 
referenced. FXII is a zymogen of a serine protease factor XIIa (FXIIa, 
EC 3.4.21.38) that becomes an enzyme by autoactivation on artifi‐
cial and biologic surfaces or by activation by another serine protease 
such as plasma kallikrein (PKa, EC 3.4.21.34) or plasmin. Plasma PK is 
a zymogen that is activated to PKa by FXIIa and other proteases. PK 
and FXI circulate and bind to cells in the intravascular compartment 
in complex with HK. In addition to its carrier function, HK is a cofac‐
tor for FXIIa and PKa activities. It is also the parent protein of the va‐
soactive peptide bradykinin (BK) that is mostly liberated from HK by 
PKa. It is well recognized that deficiencies in CS proteins, although 
having a critical role in in vitro intrinsic blood coagulation assays, 
such as the activated partial thromboplastin time (aPTT), are not as‐
sociated with excess bleeding. FXI deficiency is a bleeding state that 
is called hemophilia C.
Recently, there is new‐found interest in the CS due to the fact 
that several biologic substances, both physiologic and pathophysi‐
ologic, have been recognized as activators of FXII and, in turn, the 
intrinsic pathway of blood coagulation. These activators may include 
microbial membranes, collagen, DNA, polyphosphates, exosomes, 
and denatured and misfolded proteins. Additionally, when CS pro‐
tein expression was genetically ablated, FXII, PK, and HK deficient 
mice have reduced and/or defective vascular occlusion when com‐
pared to wild‐type animals in a variety of models of arterial and 
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venous thrombosis. These observations suggested that CS proteins 
may be targets to prevent thrombosis without altering hemostasis. 
This novel realization has attracted new interest and investigators to 
the field. As a result, there is a plethora of old and new abbreviations 
adulterating the literature by the many new investigators resulting in 
situations in which the reader does not know if the writer is describ‐
ing a zymogen or active enzyme of a protein. Thus, the Subcommittee 
on Factor XI and the Contact System agreed at the 62nd Annual ISTH 
SCC 2016 meeting in Montpellier, France to form a working group to 
review the nomenclature and recommend abbreviations that can be 
utilized in communications and investigations. The members of the 
working group are the authors of this publication. This paper is the 
first comprehensive report and recommendation of abbreviations 
for all the CS proteins and FXI. Previously, this subcommittee of the 
SSC had recommended nomenclature for both HK and L‐kininogens 
(low molecular weight kininogen, LK) and their peptide fragments.1 
The present report mostly accepts the previous report and builds 
upon it. The complete recommendations of the abbreviations for all 
the CS proteins and FXI are shown in Table 1.
Human HK (Table 1) is a single‐chain 120 kilodalton (kDa) pro‐
tein of six domains that when cleaved by PKa consists of a so‐called 
heavy chain of approximately 65 kDa consisting of domains D1‐
D3 and a light chain of approximately 56 kDa (C‐terminal domain 
of D4 and D5 and D6, Figure 1A). PKa cleaves HK liberating the 
Preferred protein 
designation Preferred abbreviation Synonyms
H‐kininogen HK High molecular weight kininogen
 High molecular mass kininogen
 HMW kininogen
 Alpha1‐cysteine proteinase 
inhibitor
 Alpha1‐thiol proteinase inhibitor
 Williams or Fitzgerald Factor










Plasma kallikrein PKa Plasma kallikrein
 PK
Factor XII FXII Zymogen Factor XII
 XII, αFXII
 Hageman Factor
Factor XIIa FXIIa Activated Factor XII
 Activated Hageman Factor
αFXIIa Activated Factor XII with full 
heavy chain
βFXIIa Activated Factor XII with small 
heavy chain
 Factor XIIa fragment
 Hageman Factor fragment, HFf
Factor XI FXI Factor XI
 XI, Rosenthal Factor
Factor XIa FXIa Activated FXI
aApproved at the meeting of the SSC subcommittee on Factor XI and the Contact System in Dublin, 
Ireland in 2018. 
TA B L E  1   Proposed nomenclature for 
Factor XI and the Contact Systema 
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vasoactive peptide bradykinin (BK, Table 1) that consists of 9 amino 
acids, RPPGFSPFR, from the small 21 amino acid domain 4 of HK 
(D4, Figure 1A). The residual HK is called cleaved HK (cHK) with its 
heavy and light chains connected by a disulfide bond. Human HK 
is one of two kininogens (HK and LK) that arise from a single gene 
(Kgn1), but alternative splicing in exon 10 produces two proteins.1 
F I G U R E  1   Cartoon characterization of each of the proteins of the human contact system. Panel A. The structure of H‐kininogen (HK) 
is shown. It is a single‐chain polypeptide consisting of a heavy chain (H‐chain) (domains 1‐3) and a light chain (L‐chain) (the C‐terminal part 
of domain 4 and domains 5 and 6). Domain 4 consists of the bradykinin (BK) peptide RPPGFSPFR and an additional 12 amino acids at the 
C‐terminus. These latter 12 amino acids of D4 are considered part of the light chain (L‐chain) of HK. Domain 5 of HK starts after these 12 
amino acids. When cleaved to liberate BK, the residual cleaved H‐kininogen (cHK) functions as a biomarker for contact system activation. 
Panel B. Plasma prekallikrein (PK) is a single‐chain zymogen. When activated to a serine protease, plasma kallikrein (PKa) has a heavy (H) 
and light (L) chain held together by an intramolecular disulfide bond. Panel C. Factor (FXII) also is a single‐chain zymogen. When formed into 
an active enzyme (αFXIIa), it too has a heavy (H) and light (L) chain held together by an intramolecular disulfide bond. If the heavy chain for 
αFXIIa is lost, the enzyme loses its ability to attach to surfaces and becomes a fluid‐phase activator (βFXIIa) of its substrates. Panel D. Factor 
XI (FXI) is a dimer of two single‐chain identical polypeptides. Upon activation to factor XIa (FXIa), the protein consists of four polypeptides, 
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LK has a short light chain and does not bind to PK or FXI and has no 
procoagulant activity.1 As a result, it is not a “classical” member of 
the CS family and is not considered further in this report. When HK 
is cleaved and BK is liberated, the residual BK‐free HK has a consid‐
erably long half‐life in the intravascular compartment compared to 
the BK peptide that is degraded within minutes. Cleaved HK (cHK, 
Table 1), as detected on immunoblot or ELISA or by its fragments on 
mass spectrometry, is now recognized as a relatively stable plasma 
biomarker of prior CS activation (Figure 1A).
Plasma prekallikrein (PK, Table 1) is an 88 kDa single‐chain pro‐
tein zymogen. When PK is activated to plasma kallikrein (PKa, EC 
3.4.21.34), it consists of a N‐terminal heavy (50 kDa) and C‐terminal 
light (30 kDa) chains (Figure 1B) linked by a disulfide bond. The enzy‐
matic activity of PKa is contained in its C‐terminal light chain (protease 
domain). The abbreviation PK for plasma prekallikrein was chosen due 
to its long‐standing use and recognition in the field. PK is converted 
into the serine protease plasma kallikrein (PKa, Table 1) by FXIIa. The 
major substrates of PKa are zymogen FXII and HK. Additional potential 
substrates of PKa include plasminogen, plasma prorenin, complement 
factor 3, and protease‐activated receptor‐1. The activation of FXII by 
PKa leads to additional PK activation and reciprocal amplification of 
the entire system. Cleavage of HK with the liberation of BK results in 
activation of the plasma kallikrein/kinin system and stimulation of the 
vasculature's BK receptor system. The abbreviation of PKa for plasma 
kallikrein was agreed upon because it was the least ambiguous and 
is consistent with the convention of nomenclature of activated forms 
of the serine proteases of the plasma blood coagulation system. PK 
is encoded by the KLKB1 gene and is distinct from other kallikreins 
including the KLK1 gene product tissue kallikrein, which displays kini‐
nogenase activity cleaving LK to generate Lys‐bradykinin.
FXII (Table 1) also is a single‐chain 80 kDa protein zymogen 
(Figure 1C). Structurally it is similar to single‐chain urokinase and 
hepatocyte growth factor activator. Following zymogen activation, 
the active serine protease FXIIa consists of a heavy chain of 50 kDa 
linked to a light chain of 30 kDa by a disulfide bond. The serine 
protease active site of FXIIa is contained in its light chain. When 
plasma FXII is activated to a serine protease (FXIIa, EC 3.4.21.38) 
(Table 1, Figure 1C) by PKa or plasmin it acts on various substrates 
that include PK, FXII, plasminogen, C1r, C1s, and factor VII. It is rec‐
ognized that there are at least two forms of activated FXII (FXIIa). 
αFXIIa (Table 1) retains a fully intact heavy chain (Figure 1C). βFXIIa 
(Table 1) is also a two‐chain protein, but it is missing the majority 
of its heavy chain and has been called FXIIa fragment or Hageman 
Factor fragment (Figure 1C). βFXIIa has potent enzymatic activity 
and is a fluid‐phase activator of PK and plasminogen. The subcom‐
mittee recognizes that much work currently is being performed on 
FXII as a single‐chain protein with detectable enzymatic activity 
in the absence and presence of surfaces. This area is under active 
investigation and it was agreed to withhold recommendations of 
new abbreviation designations for future nomenclature revisions.
FXI (Table 1) is a two‐chain 160 kDa protein consisting of two 
identical 80 kDa chains held together by a single intramolecular 
disulfide bond, although the disulfide is not essential for it to be 
a dimer (Figure 1D). Structurally each FXI subunit is similar to 
PK. When FXI is activated to an active serine protease (FXIa, EC 
3.4.21.27, Table 1) by FXIIa or thrombin, each monomer is con‐
verted to a heavy chain of 50 kDa and a light chain of 30 kDa 
(Figure 1D) that remain connected by a disulfide bond. The serine 
protease active sites of FXIa are contained in its light chains. FXIa 
activates zymogen blood coagulation factor IX in the absence of 
any known protein cofactor.
The nomenclature proposal contained in this document was re‐
peatedly circulated to the working group members between 2016 
and 2019. After the 2017 ISTH meeting in Berlin, the subcommittee 
circulated the nomenclature proposal (Table 1) to the more than 200 
contributors of the Factor XI and the Contact System Subcommittee. 
The proposal was adopted unanimously by the Subcommittee on 
Factor XI and the Contact System at its business meeting during the 
SSC meeting in Dublin, Ireland in 2018.
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